Carlos Figueroa
About Carlos Figueroa
Carlos Figueroa is a scientist with extensive experience in chemical engineering and biopharmaceutical research. He currently works at Insmed Incorporated, focusing on intracellular delivery methods for antibiotics and novel liposomal formulations for orphan respiratory diseases.
Work at Insmed
Carlos Figueroa has been employed at Insmed Incorporated since 2015. He holds the position of Scientist, where he investigates intracellular delivery methods for antibiotics, focusing on endosomal escape formulations. In addition to his role as a Scientist, he has also worked as a Temporary Scientist at Insmed. His responsibilities include optimizing formulations and evaluating scalable manufacturing processes. He collaborates with a team of senior scientists and other research professionals to meet project deliverables.
Education and Expertise
Carlos Figueroa studied Chemical Engineering at New Jersey Institute of Technology, where he earned a Bachelor of Science degree from 2006 to 2009. He further pursued advanced studies at Princeton University, obtaining a Master of Arts and a Doctor of Philosophy in Chemical Engineering and Philosophy from 2009 to 2014. He is currently pursuing a Master of Science in biopharmaceutical engineering through night classes to enhance his expertise in bio-molecules.
Background
Carlos Figueroa completed his high school education at Columbia High School from 2002 to 2006. His professional experience includes internships at Merck and Novartis, where he gained practical knowledge in the pharmaceutical industry. He also worked as a Graduate Research Assistant at Princeton University from 2010 to 2014, contributing to various research projects. Prior to his current role at Insmed, he served as a Senior Associate Scientist at Bayer Healthcare from 2014 to 2015.
Achievements
During his career, Carlos Figueroa contributed to the formulation and process development of Alka-Seltzer Plus Severe Cold & Cough Liquid Night. His research focuses on novel liposomal formulations for orphan respiratory diseases and includes developing release assays for model fluorophores. He conducts preformulation and HPLC method development for small molecule candidates in sarcoidosis treatment, showcasing his commitment to advancing pharmaceutical sciences.